Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patients and data tracking

- PMLiVE

EU approval for Lilly’s Cyramza in stomach cancer

Follows shortly after the drug's US approval in non-small cell lung cancer

- PMLiVE

Sovaldi dropped by Express Scripts in favour of Viekira Pak

Pharmacy benefits organisation ramps up US pricing pressure on Gilead

Bristol-Myers Squibb (BMS) building

BMS cancer drug Opdivo gains US melanoma licence

Therapeutic vaccine can now be used against the deadliest form of skin cancer

- PMLiVE

FDA backs Cubist’s antibiotic Zerbaxa

Combination cephalosporin and beta lactamase inhibitor wins US approval

The impending threat of antibiotic resistance

Antibiotic Research UK is the BIA's charity of 2015, but what does it intend to do?

Pharma’s pigeons

If it can adapt, a lucrative new niche is opening up for pharma

- PMLiVE

CRF Health boosts leadership team

John Blakely and Risto Enbuska join the electronic patient reported outcomes firm

- PMLiVE

AbbVie wins key approval for hep C pill Viekira Pak

Prices all-oral treatment fractionally lower than rivals from Gilead

Eli Lilly HQ

Lilly signs $570m deal for next-gen Humalog

Licenses improved version of its insulin blockbuster from Adocia

UK Life Sciences Strategy - one year on

NHS set to deliver ‘world-leading’ genomics centres

Genetics research plans could help create more bespoke medicines

- PMLiVE

GSK squares up to Merck with shingles vaccine data

Trial shows vaccine cut the risk of shingles in over 50s by 97%

- PMLiVE

Orexigen’s obesity pill Mysimba set for European approval

But sales of the treatment are only predicted to reach $200m by 2016

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links